- Home
- BMRC vs TRVI Comparison
BMRC vs TRVI Comparison
Compare BMRC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- TRVI
- Stock Information
- Founded
- BMRC 1989
- TRVI 2011
- Country
- BMRC United States
- TRVI United States
- Employees
- BMRC N/A
- TRVI N/A
- Industry
- BMRC Major Banks
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- BMRC Finance
- TRVI Health Care
- Exchange
- BMRC Nasdaq
- TRVI Nasdaq
- Market Cap
- BMRC 334.0M
- TRVI 341.4M
- IPO Year
- BMRC N/A
- TRVI 2019
- Fundamental
- Price
- BMRC $23.70
- TRVI $3.56
- Analyst Decision
- BMRC Strong Buy
- TRVI Strong Buy
- Analyst Count
- BMRC 3
- TRVI 8
- Target Price
- BMRC $28.00
- TRVI $9.31
- AVG Volume (30 Days)
- BMRC 54.3K
- TRVI 659.4K
- Earning Date
- BMRC 01-27-2025
- TRVI 03-19-2025
- Dividend Yield
- BMRC 4.21%
- TRVI N/A
- EPS Growth
- BMRC N/A
- TRVI N/A
- EPS
- BMRC N/A
- TRVI N/A
- Revenue
- BMRC $59,368,000.00
- TRVI N/A
- Revenue This Year
- BMRC N/A
- TRVI N/A
- Revenue Next Year
- BMRC $13.55
- TRVI N/A
- P/E Ratio
- BMRC N/A
- TRVI N/A
- Revenue Growth
- BMRC N/A
- TRVI N/A
- 52 Week Low
- BMRC $14.11
- TRVI $1.30
- 52 Week High
- BMRC $27.11
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- BMRC 50.49
- TRVI 43.13
- Support Level
- BMRC $23.10
- TRVI $3.63
- Resistance Level
- BMRC $24.00
- TRVI $4.06
- Average True Range (ATR)
- BMRC 0.79
- TRVI 0.30
- MACD
- BMRC 0.07
- TRVI -0.11
- Stochastic Oscillator
- BMRC 66.79
- TRVI 0.44
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.